SEGMENT INFORMATION (Tables)

6 Months Ended

Apr. 30, 2023

Segment Profitability and Segment Assets

The profitability of each of the segments is measured after excluding items such as transformational initiatives, acquisition and integration costs, amortization of intangible assets related to business combinations, interest income, interest expense and other items as noted in the reconciliations below:


	Three Months Ended				Six Months Ended
	April 30,				April 30,
	2023		2022		2023		2022
	(in millions)
Net Revenue:
Life Sciences and Applied Markets	$	968	$	896	$	2,001	$	1,872
Diagnostics and Genomics	362		358		704		697
Agilent CrossLab	387		353		768		712
Total net revenue	$	1,717	$	1,607	$	3,473	$	3,281

Segment Income From Operations:
Life Sciences and Applied Markets	$	264	$	228	$	578	$	510
Diagnostics and Genomics	73		91		132		159
Agilent CrossLab	103		87		206		178
Total segment income from operations	$	440	$	406	$	916	$	847

The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, short-term and long-term investments, deferred tax assets, right-of-use assets and other assets.


	April 30, 2023		October 31, 2022
	(in millions)
Segment Assets:
Life Sciences and Applied Markets	$	3,969	$	3,955
Diagnostics and Genomics	3,549		3,489
Agilent CrossLab	946		869
Total segment assets	$	8,464	$	8,313

Reconciliation of segment results to total enterprise results

The following table reconciles segment income from operations to Agilent’s total enterprise income before taxes:


	Three Months Ended				Six Months Ended
	April 30,				April 30,
	2023		2022		2023		2022
	(in millions)
Total segment income from operations	$	440	$	406	$	916	$	847
Transformational initiatives	(5)		(9)		(12)		(13)
Amortization of intangible assets related to business combinations	(38)		(50)		(74)		(101)
Acquisition and integration costs	(5)		(8)		(7)		(15)

Change in fair value of contingent consideration	—		28		(1)		25

Business exit and divestiture costs	—		(7)		—		(7)



Other	(9)		—		(13)		—
Interest income	12		1		21		2
Interest expense	(24)		(21)		(49)		(42)
Other income (expense), net (1)	6		(7)		6		(44)
Income before taxes, as reported	$	377	$	333	$	787	$	652

(1) For the three and six months ended April 30, 2023 and 2022, other income (expense), net includes net (gains) losses on the fair value of equity securities.